Rajkotupdates.news : zydus needle free corona vaccine zycov d

Zydus Needle-Free Corona Vaccine – Zycov-D: A Game Changer in the Fight Against COVID-19

Rajkotupdates.news : zydus needle free corona vaccine zycov d, The COVID-19 pandemic has wreaked havoc across the world, and the only way out of this crisis is through vaccination. While several vaccines have been developed and administered globally, the need for an effective, safe, and easy-to-administer vaccine remains crucial. The Zydus Cadila vaccine, Zycov-D, is one such vaccine that has gained significant attention and is being considered a game-changer in the fight against COVID-19.

Here is a detailed article on the Zydus needle-free corona vaccine – Zycov-D, highlighting its features, clinical trials, efficacy, and availability.

Overview of Zycov-D

Rajkotupdates.news : zydus needle free corona vaccine zycov d, Zycov-D is a three-dose DNA-based vaccine developed by Zydus Cadila, an Indian pharmaceutical company. It is a needle-free vaccine administered using a needle-free injector called “PharmaJet,” which uses high-pressure streams of fluid to deliver the vaccine through the skin.

ZyCoV-D To Be India's Fourth Covid Vaccine | Coronavirus Vaccine Update |  Breaking News - YouTube

The vaccine works by introducing a small piece of DNA into the body, which instructs the cells to produce a protein called the spike protein found on the surface of the coronavirus. This protein triggers an immune response that builds immunity against the virus.

Clinical Trials of Zycov-D

Rajkotupdates.news : zydus needle free corona vaccine zycov d, The clinical trials for Zycov-D began in July 2020, and the vaccine has completed Phase I and Phase II trials with promising results. The Phase III trials of the vaccine began in December 2020 and were conducted on 28,000 volunteers aged between 12 and 65 years in over 50 sites across India. The trials were randomized, double-blind, and placebo-controlled.

The interim results of the Phase III trials, released in August 2021, showed that the vaccine was 66.6% effective against symptomatic COVID-19 infections. The vaccine also showed 100% efficacy against moderate to severe disease and hospitalization.

The trials also showed that the vaccine was well-tolerated, with no severe adverse effects reported. The most common side effects reported were mild to moderate injection site pain and fever.

Efficacy of Zycov-D

The Zydus Cadila vaccine has shown promising results in clinical trials, with 66.6% efficacy against symptomatic COVID-19 infections. The vaccine has also shown 100% efficacy against moderate to severe disease and hospitalization.

The efficacy of the vaccine against the Delta variant of the coronavirus, which is highly infectious and responsible for the second wave of COVID-19 in India, is yet to be determined. However, the developers of the vaccine have stated that they are confident that the vaccine will be effective against the Delta variant.

Zydus Cadila to supply 1 crore doses of COVID-19 vaccine ZyCoV-D to Indian  govt - BusinessToday

Availability of Zycov-D

Rajkotupdates.news : zydus needle free corona vaccine zycov d, Zydus Cadila has applied for emergency use authorization (EUA) for its vaccine in India, and the approval is pending. The company has also applied for EUA in several other countries, including Brazil, the Philippines, and Mexico.

The vaccine is expected to be priced at around INR 1,000 ($13.5) per dose, making it one of the most affordable COVID-19 vaccines available. The vaccine can be stored at 2-8°C, making it easy to transport and store.

Conclusion

The Zydus Cadila vaccine, Zycov-D, is a promising vaccine that has shown good efficacy and safety results in clinical trials. The needle-free administration of the vaccine makes it easy to administer, and the affordability and easy storage requirements make it accessible to people in low- and middle-income countries.

The vaccine’s approval and availability in India and other countries are eagerly awaited, and it is hoped that it will be a game-changer in the fight against COVID-19.

FAQ

Here are some frequently asked questions about the Zydus needle-free corona vaccine – Zycov-D:

What is Zycov-D?

Zycov-D is a three-dose DNA-based vaccine developed by Zydus Cadila, an Indian pharmaceutical company, to protect against COVID-19.

How is Zycov-D administered?

Zycov-D is administered using a needle-free injector called “PharmaJet,” which uses high-pressure streams of fluid to deliver the vaccine through the skin.

How effective is Zycov-D?

The interim results of the Phase III trials showed that the vaccine was 66.6% effective against symptomatic COVID-19 infections. The vaccine also showed 100% efficacy against moderate to severe disease and hospitalization.

Are there any side effects of Zycov-D?

The vaccine was well-tolerated, with no severe adverse effects reported. The most common side effects reported were mild to moderate injection site pain and fever.

Is Zycov-D approved for use?

Zydus Cadila has applied for emergency use authorization (EUA) for its vaccine in India, and the approval is pending. The company has also applied for EUA in several other countries, including Brazil, the Philippines, and Mexico.

Must read=Rajkotupdates.news : america granted work permits for indian spouses of h-1 b visa holders

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *